This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05403177
Recruitment Status : Recruiting
First Posted : June 3, 2022
Last Update Posted : June 5, 2023
Sponsor:
Collaborators:
Princess Margaret Hospital, Canada
Ontario Institute for Cancer Research
Terry Fox Research Institute
Information provided by (Responsible Party):
University Health Network, Toronto

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Condition or disease
Breast Cancer Colorectal Cancer Pancreas Cancer Kidney Cancer Prostate Cancer Ovary Cancer Head and Neck Cancer Leukemia Lymphoma Lung Cancer Melanoma Solid Tumor

Detailed Description:
The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
Actual Study Start Date : June 23, 2022
Estimated Primary Completion Date : October 2026
Estimated Study Completion Date : October 2026

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
MOHCCN-O
Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases [ Time Frame: 5 years ]
  2. Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions [ Time Frame: 5 years ]
    Health technology assessment tools will be used to evaluate the real-world value of precision medicine

  3. Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine [ Time Frame: 5 years ]
    Health technology assessment tools will be used to evaluate the real-world value of precision medicine


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any cancer patient
Criteria

Inclusion Criteria:

  1. Patients with histological and cytological confirmation of blood or solid tumor malignancies.

  2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

    • existing data that satisfies the minimal requirements of a gold standard case, AND/OR
    • previously collected and sufficient biospecimens (tumor and/or blood samples) for whole-genome and transcriptome sequencing and immunophenotype characterization, AND/OR
    • new blood collection and/or tumor biopsy
  3. Agrees to share anonymized clinical and genomic data.

Exclusion Criteria:

None.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05403177


Contacts
Layout table for location contacts
Contact: PM2C Central Office 416.946.4501 ext 3486 MOHCCN@uhn.ca

Locations
Layout table for location information
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G2M9
Contact: PM2C Central Office    416-946-4501 ext 3486    MOHCCN@uhn.ca   
Principal Investigator: Lillian Siu, MD         
Sponsors and Collaborators
University Health Network, Toronto
Princess Margaret Hospital, Canada
Ontario Institute for Cancer Research
Terry Fox Research Institute
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT05403177    
Other Study ID Numbers: MOHCCN-O
First Posted: June 3, 2022    Key Record Dates
Last Update Posted: June 5, 2023
Last Verified: June 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Neoplasms
Pancreatic Neoplasms
Ovarian Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases
Urogenital Diseases
Male Urogenital Diseases
Digestive System Neoplasms
Digestive System Diseases
Urologic Neoplasms
 Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Kidney Diseases
Urologic Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders